{"change_dates":[],"dossier":{"amendments":[],"changes":{"2014-11-10T01:10:04":[{"data":[{"body":"EC","commission":[{"Commissioner":"VASSILIOU Androulla","DG":{"title":"Health and Consumers","url":"http://ec.europa.eu/dgs/health_consumer/index_en.htm"}}],"date":"2007-06-04T00:00:00","docs":[{"celexid":"CELEX:52007PC0292:EN","text":["
PURPOSE: to\n amend Council Directive 96/22/EC concerning the prohibition on the use in stock\n farming of certain substances having a hormonal or thyreostatic action and of\n beta-agonists.
PROPOSED ACT:\n Directive of the European Parliament and of the Council.
CONTENT: this\n proposal aims to:
Article 2 (a)\n of Council Directive 96/22/EC specifically prohibits the placing on the\n market of substances listed in Annex II for administering to animals of\n \"all species\". The motive behind the prohibition of substances for\n all species is that misuse would be more difficult if no product authorised\n for whatever species were on the market.
Several Member States and the veterinary pharmaceutical industry complained to the Commission services\n that marketing authorisations cannot be granted for products containing\n substances to treat hyperthyroidism in pet animals due to the restrictions of\n Directive 96/22/EC. They appealed to the Commission to mitigate the\n situation.
As regards\n Oestradiol 17ß and its ester like derivates, it appears that the use of the\n alternative substances such as prostaglandins is already common.\n Veterinarians predict an insignificant impact of future unavailability of\n oestradiol 17ß and its ester like derivates on farmers and on animal welfare.\n It is also observed that the unavailability of oestradiol and its ester like\n derivates would have minimal economic effect. This is because the incidence\n of fetal mummification and fetal maceration is low, and although the incidence\n of pyometra is higher, methods of prevention not involving use of oestradiol\n do exist and would be preferable.
Member States and the veterinary pharmaceutical\n industry provided their opinion on thyrostatic substances. The Member States\n have also confirmed in a Council meeting on 11 October 2005 in July 2006 that if oestradiol 17ß and its ester like derivates were to be prohibited for food\n producing animals, the substance should remain available for pet animals.
\nThe Council\n reached a general approach on a proposal for a Directive amending Council\n Directive 96/22/EC concerning the prohibition on the use in stockfarming of\n certain substances having a hormonal or thyrostatic action and of beta\n agonists.
The agreed text\n will serve as a basis for informal trilogue discussions with the European\n Parliament in view of a first reading agreement.
The proposal\n is aimed at taking pet animals out of the scope of the legislation and\n prohibiting the use of oestradiol 17ß in food producing animals entirely. In addition, the definition\n of therapeutic treatment was adjusted, in particular with regard to the use\n of beta-agonists.
\nThe Committee\n on the Environment, Public Health and Food Safety adopted a report drafted by\n Karin SCHEELE (PES, AT), and amended, in the first reading of the\n codecision procedure, the proposal for a directive of the European Parliament\n and of the Council amending Council Directive 96/22/EC concerning the prohibition\n on the use in stockfarming of certain substances having a hormonal or\n thyreostatic action and of beta-agonists.
The main\n amendments are as follows:
The European\n Parliament adopted, by 692 votes to 2 with 11 abstentions, a legislative\n resolution making some amendments to the proposal for a directive of the\n European Parliament and of the Council amending Council Directive 96/22/EC\n concerning the prohibition on the use in stockfarming of certain substances\n having a hormonal or thyreostatic action and of beta-agonists. The report had\n been tabled for consideration in plenary by Karin SCHEELE (PES, AT) on\n behalf of the Committee on the Environment, Public Health and Food Safety.
The main\n amendments – adopted under the 1st reading of the codecsion procedure – are\n as follows:
-the\n definition of 'therapeutic treatment' has been amended;
-Member States\n should be allowed to authorise the use of beta-agonists to treat respiratory\n problems, navicular disease and laminitis in horse raised for purposes other\n than meat production since alternatives are limited;
-the\n Commission, in collaboration with the Member States, shall set up an\n information and awareness campaign on the complete ban on the use of\n oestradiol 17 ß in food producing animals, aimed at farmers and veterinary\n organisations in the EU as well as the relevant organisations outside the EU\n which are directly or indirectly involved in the export to the EU of food of\n animal origin falling within the scope of this Directive;
-Annex II is\n amended to clarify that beta-agonist, although prohibited in general, may be\n used in certain specific cases;
-lastly,\n transposition of the Directive should be by 1 January 2009 (rather than 1\n July 2007).
\nPURPOSE: to\n amend current legislation on the use in stockfarming of certain substances\n having a hormonal or thyrostatic action and of beta-agonists.
LEGISLATIVE\n ACT: Directive 2008/97/EC of the European Parliament and of the Council\n amending Council Directive 96/22/EC concerning the prohibition on the\n use in stockfarming of certain substances having a hormonal or thyrostatic\n action and of beta-agonists.
CONTENT:\n having reached agreement with the European Parliament at first reading, the\n Directive definitively prohibits the administration of oestradiol 17 B to any\n animal in order to guarantee the highest level of health protection and\n authorises the use of stilbenes, stilbene derivatives, their salts and esters\n or of thyrostatic substances for pet animals on animal welfare grounds.\n Member States shall be allowed to authorise the use of beta-agonists to treat\n horses raised for purposes other than meat production, provided they are used\n in accordance with the manufacturer’s instructions.
The\n Commission, in collaboration with the Member States, shall set up an\n information and awareness campaign on the complete ban on the use of\n oestradiol 17β in food-producing animals, aimed at farmers and\n veterinary organisations in the EU as well as the relevant organisations\n outside the EU which are directly or indirectly involved in the export to the\n EU of food of animal origin falling within the scope of the Directive.
ENTRY INTO\n FORCE: 18/12/2008.
TRANSPOSITION:\n 01/01/2009.
\nPURPOSE: to\n amend Council Directive 96/22/EC concerning the prohibition on the use in stock\n farming of certain substances having a hormonal or thyreostatic action and of\n beta-agonists.
PROPOSED ACT:\n Directive of the European Parliament and of the Council.
CONTENT: this\n proposal aims to:
Article 2 (a)\n of Council Directive 96/22/EC specifically prohibits the placing on the\n market of substances listed in Annex II for administering to animals of\n \"all species\". The motive behind the prohibition of substances for\n all species is that misuse would be more difficult if no product authorised\n for whatever species were on the market.
Several Member States and the veterinary pharmaceutical industry complained to the Commission services\n that marketing authorisations cannot be granted for products containing\n substances to treat hyperthyroidism in pet animals due to the restrictions of\n Directive 96/22/EC. They appealed to the Commission to mitigate the\n situation.
As regards\n Oestradiol 17ß and its ester like derivates, it appears that the use of the\n alternative substances such as prostaglandins is already common.\n Veterinarians predict an insignificant impact of future unavailability of\n oestradiol 17ß and its ester like derivates on farmers and on animal welfare.\n It is also observed that the unavailability of oestradiol and its ester like\n derivates would have minimal economic effect. This is because the incidence\n of fetal mummification and fetal maceration is low, and although the incidence\n of pyometra is higher, methods of prevention not involving use of oestradiol\n do exist and would be preferable.
Member States and the veterinary pharmaceutical\n industry provided their opinion on thyrostatic substances. The Member States\n have also confirmed in a Council meeting on 11 October 2005 in July 2006 that if oestradiol 17ß and its ester like derivates were to be prohibited for food\n producing animals, the substance should remain available for pet animals.
\nThe Council\n reached a general approach on a proposal for a Directive amending Council\n Directive 96/22/EC concerning the prohibition on the use in stockfarming of\n certain substances having a hormonal or thyrostatic action and of beta\n agonists.
The agreed text\n will serve as a basis for informal trilogue discussions with the European\n Parliament in view of a first reading agreement.
The proposal\n is aimed at taking pet animals out of the scope of the legislation and\n prohibiting the use of oestradiol 17ß in food producing animals entirely. In addition, the definition\n of therapeutic treatment was adjusted, in particular with regard to the use\n of beta-agonists.
\nThe Committee\n on the Environment, Public Health and Food Safety adopted a report drafted by\n Karin SCHEELE (PES, AT), and amended, in the first reading of the\n codecision procedure, the proposal for a directive of the European Parliament\n and of the Council amending Council Directive 96/22/EC concerning the prohibition\n on the use in stockfarming of certain substances having a hormonal or\n thyreostatic action and of beta-agonists.
The main\n amendments are as follows:
The European\n Parliament adopted, by 692 votes to 2 with 11 abstentions, a legislative\n resolution making some amendments to the proposal for a directive of the\n European Parliament and of the Council amending Council Directive 96/22/EC\n concerning the prohibition on the use in stockfarming of certain substances\n having a hormonal or thyreostatic action and of beta-agonists. The report had\n been tabled for consideration in plenary by Karin SCHEELE (PES, AT) on\n behalf of the Committee on the Environment, Public Health and Food Safety.
The main\n amendments – adopted under the 1st reading of the codecsion procedure – are\n as follows:
-the\n definition of 'therapeutic treatment' has been amended;
-Member States\n should be allowed to authorise the use of beta-agonists to treat respiratory\n problems, navicular disease and laminitis in horse raised for purposes other\n than meat production since alternatives are limited;
-the\n Commission, in collaboration with the Member States, shall set up an\n information and awareness campaign on the complete ban on the use of\n oestradiol 17 ß in food producing animals, aimed at farmers and veterinary\n organisations in the EU as well as the relevant organisations outside the EU\n which are directly or indirectly involved in the export to the EU of food of\n animal origin falling within the scope of this Directive;
-Annex II is\n amended to clarify that beta-agonist, although prohibited in general, may be\n used in certain specific cases;
-lastly,\n transposition of the Directive should be by 1 January 2009 (rather than 1\n July 2007).
\nPURPOSE: to\n amend current legislation on the use in stockfarming of certain substances\n having a hormonal or thyrostatic action and of beta-agonists.
LEGISLATIVE\n ACT: Directive 2008/97/EC of the European Parliament and of the Council\n amending Council Directive 96/22/EC concerning the prohibition on the\n use in stockfarming of certain substances having a hormonal or thyrostatic\n action and of beta-agonists.
CONTENT:\n having reached agreement with the European Parliament at first reading, the\n Directive definitively prohibits the administration of oestradiol 17 B to any\n animal in order to guarantee the highest level of health protection and\n authorises the use of stilbenes, stilbene derivatives, their salts and esters\n or of thyrostatic substances for pet animals on animal welfare grounds.\n Member States shall be allowed to authorise the use of beta-agonists to treat\n horses raised for purposes other than meat production, provided they are used\n in accordance with the manufacturer’s instructions.
The\n Commission, in collaboration with the Member States, shall set up an\n information and awareness campaign on the complete ban on the use of\n oestradiol 17β in food-producing animals, aimed at farmers and\n veterinary organisations in the EU as well as the relevant organisations\n outside the EU which are directly or indirectly involved in the export to the\n EU of food of animal origin falling within the scope of the Directive.
ENTRY INTO\n FORCE: 18/12/2008.
TRANSPOSITION:\n 01/01/2009.
\n